AbobotulinumtoxinA + Normal saline
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Post-Traumatic Headache
Conditions
Post-Traumatic Headache
Trial Timeline
Aug 1, 2013 → Feb 2, 2017
NCT ID
NCT03928496About AbobotulinumtoxinA + Normal saline
AbobotulinumtoxinA + Normal saline is a approved stage product being developed by Ipsen for Post-Traumatic Headache. The current trial status is completed. This product is registered under clinical trial identifier NCT03928496. Target conditions include Post-Traumatic Headache.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03928496 | Approved | Completed |
Competing Products
16 competing products in Post-Traumatic Headache
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab-Gnlm | Eli Lilly | Approved | 85 |
| Quetiapine Fumarate + quetiapine fumarate placebo | AstraZeneca | Phase 3 | 77 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 23 |
| AMG 334 | Novartis | Phase 2 | 52 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Erenumab | Amgen | Phase 2 | 51 |
| PF-04457845 + Placebo | Pfizer | Phase 2 | 51 |
| Zoloft (Sertraline) | Pfizer | Phase 3 | 76 |
| Levetiracetam + Placebo | UCB | Phase 3 | 74 |
| levetiracetam + Placebo + Levetriracetam | UCB | Phase 2/3 | 62 |
| Placebo + Brexpiprazole | Lundbeck | Phase 3 | 74 |
| Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo | Lundbeck | Phase 2 | 49 |
| Nabiximols + Placebo | Jazz Pharmaceuticals | Phase 2/3 | 62 |
| 60 mg PRAX-114 or 40 mg PRAX-114 + Placebo + 40 mg PRAX-114 | Praxis Precision Medicines | Phase 2 | 49 |
| MDMA | Nautilus Biotechnology | Phase 2 | 44 |
| Tramadol + Placebo | Brain Biotech | Approved | 77 |